Viemed Healthcare (VMD) Q4 2024 earnings summary

Executive summary

• Achieved record revenue and net income in 2024, with Q4 and full-year results at the high end of expectations, driven by strong organic growth across all business segments and operational improvements.

• Expanded patient base in both vent and sleep therapy, with ventilator patient count up 14% to 11,795 and significant increases in PAP therapy and sleep resupply patients.

• Positioned as a leading in-home clinical care provider, moving beyond traditional HME services and expanding behavioral health offerings.

• Balance sheet and liquidity improved, supporting continued organic growth and potential M&A.

• Eighth consecutive year of positive net income.

Financial highlights

• FY 2024 revenue reached $224.3M (up 23% YoY), with Q4 revenue at $60.7M (up 20% YoY).

• Adjusted EBITDA was $14.2M for Q4 and $51.1M for FY 2024, up 19% YoY.

• Gross margin was 59.4% for FY 2024 and 59.5%–60% in Q4.

• Free cash flow for FY 2024 was $11.6M, down from $21.7M in FY 2023, reflecting higher capital expenditures.

• Net income for FY 2024 was $11.3M, with Q4 net income at $4.3M.

Outlook and guidance

• FY 2025 net revenue expected between $254M and $265M, implying 16% growth at the midpoint.

• Adjusted EBITDA guidance for 2025 is $54M–$58M (21%–23% margin), or 10% growth over 2024.

• CapEx in 1H 2025 expected to mirror 2H 2024, with continued ventilator fleet upgrades.

• No M&A activity assumed in guidance, but pipeline for acquisitions is active.

• Plans to aggressively expand sales force and pursue both organic and potential inorganic growth.